VCP and movement disorder: Another study suggested testing genetic mutation in FTLD with movement disorders as amotor presentation, and when CBS is present, testing first for PGRN and after, ifthe first is negative, testing for MAPT, C9orf72, CHMP2B (which encodes chargedmultivesicular body protein 2b), VCP (valosin-containing protein), FUS (whichencodes RNA-binding protein FUS- fused in sarcoma), TARDBP (TAR DNA-binding protein43) and NIFID (neuronal intermediate filament inclusion disease).50